戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 and 12 months (as assessed by means of 3-day Holter monitoring).
2 nsesophageal echocardiography and 2 weeks of Holter monitoring).
3 adequacy of MRC was assessed by using serial Holter monitoring.
4 ery 3 to 6 months by clinic review and 7-day Holter monitoring.
5 ticipants did not have at least 1 PAC during Holter monitoring.
6 hocardiography, endomyocardial biopsies, and Holter monitoring.
7                        VT was assessed using Holter monitoring.
8 mia with an event transmitter and ambulatory holter monitoring.
9 den of ectopy was quantified through 24-hour Holter monitoring.
10 puted tomography perfusion scan, and 24-hour Holter monitoring.
11 ocardiography, upright exercise testing, and Holter monitoring.
12 ity of life and for increased arrhythmias by Holter monitoring.
13 re), exercise testing, echocardiography, and Holter monitoring.
14 ause they did not have AECG ischemia on 48-h Holter monitoring.
15 Rhythm outcomes were documented using 7-days Holter monitoring.
16 dized laboratory-based speech stressor using Holter monitoring.
17 went resting electrocardiography and 24-hour Holter monitoring.
18 plantable device monitoring or three monthly Holter monitoring.
19 aging, cardiopulmonary exercise testing, and Holter monitoring.
20 ssion (n = 10 [27%], including by ECG [14%], Holter monitoring [11%], or signal-averaged ECG [14%]) w
21 ted on baseline ECG (87%) or 12-lead 24-hour Holter monitoring (13%), an electrophysiologic study (EP
22       The duration of ischemia on continuous Holter monitoring after PCI was significantly longer amo
23 AF rhythm control was determined using 7-day Holter monitoring and AF severity scale questionnaire.
24  use of signal-averaged electrocardiography, Holter monitoring and assessment of left ventricular fun
25 commonly occurred first on ECGs, followed by Holter monitoring and cardiac imaging.
26 rcise tests, exercise thallium scintigraphy, Holter monitoring and electrophysiologic study findings
27 hocardiography, surface electrocardiography, Holter monitoring and exercise testing, when applicable,
28 measured in 60 stable patients after 48-hour Holter monitoring and in 24 matched controls.
29 modification of PVC burden at follow-up with Holter monitoring and its impact on arrhythmic risk in A
30  by assessing heart rate variability on 24-h Holter monitoring and plasma norepinephrine levels durin
31  After ablation, patients underwent repeated Holter monitoring and reassessment of cardiac function.
32 cidence of ineffective capture using 12-lead Holter monitoring and to assess whether this affects res
33 gned to 24-h ambulatory electrocardiography (Holter) monitoring and who had a normal LVEF and no hist
34 al abnormalities (electrocardiography and/or Holter monitoring) and abnormal CMR results.
35 and comprehensive clinical, arrhythmia (24-h Holter monitoring) and Doppler-echocardiographic charact
36          Phenotype was ascertained with ECG, Holter monitoring, and cardiac imaging and classified by
37 e was ascertained using electrocardiography, Holter monitoring, and cardiac imaging.
38 mptoms with documentation, event monitoring, Holter monitoring, and electrocardiograms.
39 , cardiac magnetic resonance imaging (CMRI), Holter monitoring, and exercise testing.
40 r monitoring; complete evaluation [ie, ECGs, Holter monitoring, and imaging] every 2 years), younger
41 ated by 12-lead ECG, echocardiogram, 24-hour Holter monitoring, and laboratory studies.
42 , and cardiac radionuclide ventriculography, Holter monitoring, and polysomnography were done.
43 phy, nonsustained ventricular tachycardia on Holter monitoring, and unexplained prior syncope.
44 ients underwent echocardiography, ambulatory Holter monitoring, and upright exercise testing.
45 aged ECG, exercise testing, cardiac imaging, Holter-monitoring, and selective provocative drug testin
46 rved in laboratory, electrocardiographic, or Holter monitoring assessments.
47  months of follow-up using a 12-lead ECG and Holter monitoring at 3, 6, and 12 months.
48                       Rhythm was assessed by Holter monitoring at 6 and 12 months after pulmonary vei
49          One-year follow-up included 24-hour Holter monitoring at 6 and 12 months and twice monthly a
50 ent of both in-home PM and HRV using 24-hour Holter monitoring at up to five time points.
51 ncreas transplant recipients underwent 24-hr Holter monitoring before and again at 6 and 12 months po
52                                   Continuous Holter monitoring began immediately before exposure and
53 een shown to be a marker of CAN with 24-hour Holter monitoring being a robust modality to assess HRV.
54 studies, 12-lead electrocardiograms, 24-hour Holter monitoring, blood tests, and completion of Minnes
55 s included adverse events, blood tests, ECG, Holter monitoring, brain MRI and EEG.
56 latives with borderline ARVC (annual ECG and Holter monitoring; complete evaluation [ie, ECGs, Holter
57 ic G+/P- relatives (every 2 years an ECG and Holter monitoring; complete evaluation every 4 years), a
58                                       Recent Holter monitoring data have revealed a high degree of da
59 gnosis, and at least 2 additional results of Holter monitoring during follow-up were enrolled from 6
60  The maximum reduction in mean heart rate by Holter monitoring during the first 6 h in ozanimod-treat
61 nal cardiac monitoring with repeated 24-hour Holter-monitoring during the first 5 years in the outpat
62 ination, which included electrocardiography, Holter monitoring, echocardiography, bicycle ergometry,
63 cluding ECG, 2-dimensional echocardiography, Holter monitoring, exercise tolerance testing, and ajmal
64                Electrocardiographic and 24-h Holter monitoring findings closest to presentation were
65 een prespecified variables retrieved at each Holter monitoring follow-up and sustained ventricular ar
66 nical features (ie, symptoms, arrhythmias at Holter monitoring) had negligible contribution in differ
67 on cardiac ultrasonography in 100 of 195, on Holter monitoring in 2 of 192; and on hypercoagulable pa
68 cally important arrhythmias were detected by Holter monitoring in 36 out of 70 (51%) in the active gr
69  or CTA), echocardiography (TEE or TTE), and Holter monitoring in selected cases.
70 etermined before and after ablation by 7-day Holter monitoring; intermittent ECG event monitoring was
71 mic risk, but ongoing follow-up with 12-lead Holter monitoring is recommended to detect the appearanc
72 verse events at regular scheduled visits and Holter monitoring; key efficacy measures were annualized
73 were evaluated by electrocardiography (ECG), Holter monitoring, late-enhancement cardiac magnetic res
74                    Patients with ischemia on Holter monitoring (n=40) received aspirin or placebo in
75               This supports pre-implantation Holter monitoring of patients selected for CRT for optim
76 ties on the basis of electrocardiography and Holter monitoring, of whom 20 (48%) had abnormal results
77 s in patients with organic heart disease, 2) Holter monitoring or telemetry in patients known to have
78                                              Holter monitoring, or intracardiac electrophysiologic st
79              MCSF was related to ischemia on Holter monitoring (P<0.01), to low ischemic threshold du
80 cal abnormalities on electrocardiography and Holter monitoring precede detectable structural abnormal
81 Patients underwent 48-h electrocardiographic Holter monitoring quarterly to detect brief subclinical
82 ts with a definite ARVC diagnosis, available Holter monitoring results at disease diagnosis, and at l
83 24%), and echocardiography in 6 of 30 (20%); Holter monitoring revealed no abnormalities.
84                                              Holter monitoring revealed ST elevation during chest pai
85                                     In vivo, Holter monitoring revealed ventricular arrhythmias and S
86                  Electrocardiograms and 24-h Holter monitoring showed no increased incidence of atrio
87 were evaluated by electrocardiography (ECG), Holter monitoring, signal-averaged ECG, and cardiac magn
88 itoring, such as 12-lead electrocardiograms, Holter monitoring, telemetry, or event recorders.
89                                       During Holter monitoring, the sensitivity of the detection of A
90 patients with MVP, ventricular arrhythmia by Holter monitoring was frequent but rarely severe.
91                                              Holter monitoring was performed for 4.8+/-1.4 days after
92 y drug was continued for 24 to 72 hours, and Holter monitoring was performed.
93                                Biannual 96-h Holter monitoring was used to assess AF burden.
94 d corrected QT intervals were recorded; 24 h Holter monitoring was utilized to gauge efficacy of trea
95 not helpful in stratifying cardiac risk, but Holter monitoring was.
96 The clinical course, electrocardiograms, and Holter monitoring were available for review in 114 subje
97  biomarkers (lipids, HbA1c, CRP) and 24-hour Holter monitoring were obtained at baseline, 3- and 9-mo
98 aphy (SPECT) perfusion scanning, and 24-hour Holter monitoring were performed at baseline and follow-
99                              ECG and 24-hour Holter monitoring were performed biweekly.
100 axar significantly reduced early ischemia on Holter monitoring without a significant increase in majo